IRIX - IRIDEX Changes Course

2025-05-01 18:00:20 ET

Summary

• IRIDEX's strategic review ended without a major asset sale, but a $10M investment from Novel Inspiration International offers growth potential and cash stability.
• Novel's investment values IRIDEX shares at $2.00/share, significantly higher than current trading prices, indicating a belief in the company's undervaluation.
• The recent LCD change in glaucoma treatment reimbursement could significantly boost IRIDEX's glaucoma business, potentially increasing the company's market valuation.
• Despite initial disappointment with the result of the strategic review, I believe IRIDEX shares are undervalued at $1.30/share, with potential for 170-200% returns within 12–24 months.

There is no way to sugarcoat it: IRIDEX’s ( IRIX ) strategic review process ended with a thud. The strategic review was announced on August 29, 2023. Excitement around this review process built, as evidenced by the appreciation in the company’s share price following the announcement.

A big part of this excitement is because the market anticipated, as I wrote about here , that IRIX’s parts would be valued more highly than its whole. As I noted, based upon public filings and interviews with people familiar with the company, IRIX’s retina business was the company’s profitable “cash cow” that helped to somewhat offset the bleeding caused by the promising, but underperforming, retina business....

For further details see: